Effect of the blue light-blocking glasses in major depressive disorder

Effect of the blue light-blocking glasses in major depressive disorder - Effect of the blue light-blocking glasses in MDD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021216

Enrollment

Registered

2016-02-29

Start date

2016-03-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

major depressive disorder

Interventions

Wear blue light blocking glasses from 20:00 until bedtime every evening for two weeks. Wear placebo glasses (blocking only ultraviolet light) from 20:00 until bedtime every evening for two weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-V) diagnosis of major depressive disorders outpatient. 20-65 years of age, male and female. Agree to the participation in study. A score of more than 13 on the 17 item Hamilton Depressive Scale (HAM-D 17). Complain of sleep onset insomnia.

Exclusion criteria

Exclusion criteria: Patient who has difficulty in wearing of the glasses. Marked suicidal ideation. Patient who judged that a doctor was inappropriate. seasonal affective disorder, bipolar and psychotic disorders, substance abuse, shift work

Design outcomes

Primary

Measure	Time frame
VAS (visual analogue mood scales)for assessment of sleep quality baseline and after treatment (2 weeks)	—

Secondary

Measure	Time frame
HAM-D (Hamilton Rating Scale for Depression) BDI (Beck Depression Inventory) CGI (Clinical global impression) MEQ (morning and evening question) sleep daily baseline and after treatment (2 weeks)	—

Countries

Japan

Contacts

Public ContactYuichi Esaki

Okehazama Hospital Medical office

esakiz@fujita-hu.ac.jp0562-97-1361

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026